Yasunori Iwata

Yasunori Iwata

Auto-generated profile, based on publicly available information

Yasunori Iwata

Department of Nephrology and Rheumatology, Kanazawa University, Kanazawa, Japan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
HLHoang Thuy Linh
Hoang Thuy Linh
YIYasunori Iwata
Yasunori Iwata
YSYasuko Senda
Yasuko Senda
YSYukiko Sakai-Takemori
Yukiko Sakai-Takemori
YNYusuke Nakade
Yusuke Nakade
TWTakashi Wada
Takashi Wada
Significance Statement: Intestinal barrier dysfunction—a “leaky gut”—reportedly contributes to pathological processes in some diseases. In a mouse model, the authors induced diabetic kidney disease, leading to impaired intestinal integrity and inflammation, with IL-17 upregulation. This allowed intestine-derived Klebsiella oxytoca and elevated IL-17 to translocate to the circulation and kidneys, then accelerate kidney injury, especially in diabetic knockout mice lacking mitochondrial antiviral signaling protein (MAVS). Stimulation of tubular epithelial cells with K. oxytoca activated the MAVS pathway and phosphorylation of Stat3 and ERK1/2, leading to production of kidney injury molecule-1 (KIM-1). Systemic MAVS is renoprotective in diabetic mice by an intestinal protective role and the dominant inhibitory effects on suppressing KIM-1 expression under K. oxytoca supernatant or IL-17 stimulation. Controlling intestinal homeostasis may offer a therapeutic strategy in diabetic kidney disease. Background: In recent years, many studies have focused on the intestinal environment to elucidate pathogenesis of various diseases, including kidney diseases. Impairment of the intestinal barrier function, the “leaky gut,” reportedly contributes to pathologic processes in some disorders. Mitochondrial antiviral signaling protein (MAVS), a component of innate immunity, maintains intestinal integrity. The effects of disrupted intestinal homeostasis associated with MAVS signaling in diabetic kidney disease remains unclear. Methods: To evaluate the contribution of intestinal barrier impairment to kidney injury under diabetic conditions, we induced diabetic kidney disease in wild-type and MAVS knockout mice through unilateral nephrectomy and streptozotocin treatment. We then assessed effects on the kidney, intestinal injuries, and bacterial translocation. Results: MAVS knockout diabetic mice showed more severe glomerular and tubular injuries compared with wild-type diabetic mice. Owing to impaired intestinal integrity, the presence of intestine-derived Klebsiella oxytoca and elevated IL-17 were detected in the circulation and kidneys of diabetic mice, especially in diabetic MAVS knockout mice. Stimulation of tubular epithelial cells with K. oxytoca activated MAVS pathways and the phosphorylation of Stat3 and ERK1/2, leading to the production of kidney injury molecule-1 (KIM-1). Nevertheless, MAVS inhibition induced inflammation in the intestinal epithelial cells and KIM-1 production in tubular epithelial cells under K. oxytoca supernatant or IL-17 stimulation. Treatment with neutralizing anti–IL-17 antibody treatment had renoprotective effects. In contrast, LPS administration accelerated kidney injury in the murine diabetic kidney disease model. Conclusions: Impaired MAVS signaling both in the kidney and intestine contributes to the disrupted homeostasis, leading to diabetic kidney disease progression. Controlling intestinal homeostasis may offer a novel therapeutic approach for this condition.

1 June 2022 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
YIYasunori Iwata
Yasunori Iwata
YNYusuke Nakade
Yusuke Nakade
SKShinji Kitajima
Shinji Kitajima
SNShiori Nakagawa
Shiori Nakagawa
MOMegumi Oshima
Megumi Oshima
TWTakashi Wada
Takashi Wada
Recent studies have revealed the connection between amino acid chirality and diseases. We have previously reported that the gut microbiota produces various d-amino acids in a murine acute kidney injury (AKI) model. Here, we further explored the pathophysiological role of d-alanine (d-Ala) in AKI. Levels of d-Ala were evaluated in a murine AKI model. We analyzed transcripts of the N-methyl-d-aspartate (NMDA) receptor, a receptor for d-Ala, in tubular epithelial cells (TECs). The therapeutic effect of d-Ala was then assessed in vivo and in vitro. Finally, the plasma level of d-Ala was evaluated in patients with AKI. The Grin genes encoding NMDA receptor subtypes were expressed in TECs. Hypoxic conditions change the gene expression of Grin1, Grin2A, and Grin2B. d-Ala protected TECs from hypoxia-related cell injury and induced proliferation after hypoxia. These protective effects are associated with the chirality of d-Ala. d-Ala inhibits reactive oxygen species (ROS) production and improves mitochondrial membrane potential, through NMDA receptor signaling. The ratio of d-Ala to l-Ala was increased in feces, plasma, and urine after the induction of ischemia-reperfusion (I/R). Moreover, Enterobacteriaceae, such as Escherichia coli and Klebsiella oxytoca, produce d-Ala. Oral administration of d-Ala ameliorated kidney injury after the induction of I/R in mice. Deficiency of NMDA subunit NR1 in tubular cells worsened kidney damage in AKI. In addition, the plasma level of d-Ala was increased and reflected the level of renal function in patients with AKI. In conclusion, d-Ala has protective effects on I/R-induced kidney injury. Moreover, the plasma level of d-Ala reflects the estimated glomerular filtration rate in patients with AKI. d-Ala could be a promising therapeutic target and potential biomarker for AKI. NEW & NOTEWORTHY d-Alanine has protective effects on I/R-induced kidney injury. d-Ala inhibits ROS production and improves mitochondrial membrane potential, resulting in reduced TEC necrosis by hypoxic stimulation. The administration of d-Ala protects the tubules from I/R injury in mice. Moreover, the plasma level of d-Ala is conversely associated with eGFR in patients with AKI. Our data suggest that d-Ala is an appealing therapeutic target and a potential biomarker for AKI.

22 May 2021 in Toxins
Verified
Journal Article
Open access
PDF file
TKTaku Kobayashi
Taku Kobayashi
YIYasunori Iwata
Yasunori Iwata
YNYusuke Nakade
Yusuke Nakade
TWTakashi Wada
Takashi Wada
Recent studies have revealed that the gut microbiota plays a crucial role in maintaining a healthy, as well as diseased condition. Various organs and systems, including the kidney, are affected by the gut microbiota. While the impacts of the gut microbiota have been reported mainly on chronic kidney disease, acute kidney injury (AKI) is also affected by the intestinal environment. In this review, we discussed the pathogenesis of AKI, highlighting the relation to the gut microbiota. Since there is no established treatment for AKI, new treatments for AKI are highly desired. Some kinds of gut bacteria and their metabolites reportedly have protective effects against AKI. Current studies provide new insights into the role of the gut microbiota in the pathogenesis of AKI.

22 January 2009 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
YIYasunori Iwata
Yasunori Iwata
KFKengo Furuichi
Kengo Furuichi
NSNorihiko Sakai
Norihiko Sakai
HYHiroyuki Yamauchi
Hiroyuki Yamauchi
YSYasuyuki Shinozaki
Yasuyuki Shinozaki
TWTakashi Wada
Takashi Wada
Objective.: Dendritic cells (DC) contribute to autoimmune disease progression and pathogenesis. Mature DC have been reported to secrete high mobility group box protein (HMGB-1), a novel inflammatory cytokine, via p38 mitogen-activated protein kinase (MAPK) activation. We investigated whether DC are involved in progression of autoimmune diseases followed by secretion of HMGB-1 via p38 MAPK activation in a lupus-prone mouse model.Methods.: FR167653, a specific inhibitor of p38 MAPK, was given orally from 3 months of age in MRL-Faslpr mice. Cultured DC, treated with or without FR167653, were stimulated with tumor necrosis factor-α.Results.: Inhibition of p38 MAPK led to a reduction in the number of CD11c-positive cells, including those with the mature phenotype, in the diseased kidney and spleen, which resulted in improvement of kidney pathology in MRL-Faslpr mice. The number of CD11c-positive cells in circulation was also reduced. HMGB-1 protein and transcripts detected in the diseased kidney, and the number of cells dual-positive for HMGB-1 and CD11c, were reduced by inhibition of p38 MAPK. Maturation of cultured DC and increased cytokines, including HMGB-1, in the supernatant were inhibited by FR167653 treatment. These results suggest that DC are involved in the progression of autoimmune kidney diseases in MRL-Faslpr mice followed by HMGB-1 secretion via p38 MAPK activation.Conclusion.: Our results indicated that DC secrete HMGB-1 via p38 MAPK activation to participate in autoimmunity in MRL-Faslpr mice.

16 December 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YNYusuke Nakade
Yusuke Nakade
YIYasunori Iwata
Yasunori Iwata
NSNorihiko Sakai
Norihiko Sakai
MMMasashi Mita
Masashi Mita
MNMaiko Nakane
Maiko Nakane
TWTakashi Wada
Takashi Wada
The number of patients on hemodialysis is increasing globally; diabetes mellitus (DM) complications is the major cause of hemodialysis in patients with chronic kidney disease (CKD). The d-amino acid (AA) profile is altered in patients with CKD; however, it has not been studied in patients with CKD and DM. Furthermore, bacteria responsible for altering the D-AA profile are not well understood. Therefore, we examined the D-AA profiles and associated bacteria in patients with CKD, with and without DM. We enrolled 12 healthy controls and 54 patients with CKD, with and without DM, and determined their salivary, stool, plasma, and urine chiral AA levels using two-dimensional high-performance liquid chromatography. We performed 16S rRNA gene sequencing analysis of the oral and gut microbiota to determine the association between the abundance of bacterial species and D-AA levels. Plasma d-alanine and d-serine levels were higher in patients with CKD than in healthy adults (p < 0.01), and plasma d-alanine levels were higher in patients with CKD and DM than in those without DM. The abundance of salivary Streptococcus, which produced d-alanine, increased in patients with CKD and DM and was positively correlated with plasma d-alanine levels. Patients with CKD and DM had unique oral microbiota and d-alanine profiles. Plasma d-alanine is a potential biomarker for patients with CKD and DM.

20 November 2015 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
KKKiyoki Kitagawa
Kiyoki Kitagawa
KFKengo Furuichi
Kengo Furuichi
ASAkihiro Sagara
Akihiro Sagara
YSYasuyuki Shinozaki
Yasuyuki Shinozaki
SKShinji Kitajima
Shinji Kitajima
HYHypertension
Hypertension